Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors.

[1]  Vsevolod A. Peshkov,et al.  Allosteric Indole Amide Inhibitors of p97: Identification of a Novel Probe of the Ubiquitin Pathway. , 2016, ACS medicinal chemistry letters.

[2]  D. Backos,et al.  Strategies and Approaches of Targeting STAT3 for Cancer Treatment. , 2016, ACS chemical biology.

[3]  P. Wipf,et al.  Structure-Activity Study of Bioisosteric Trifluoromethyl and Pentafluorosulfanyl Indole Inhibitors of the AAA ATPase p97. , 2015, ACS medicinal chemistry letters.

[4]  G. M. Wilson,et al.  HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines. , 2015, Assay and drug development technologies.

[5]  C. Watson,et al.  STAT3 the oncogene – still eluding therapy? , 2015, The FEBS journal.

[6]  J. Bajorath,et al.  Active compounds from a diverse library of triazolothiadiazole and triazolothiadiazine scaffolds: synthesis, crystal structure determination, cytotoxicity, cholinesterase inhibitory activity, and binding mode analysis. , 2014, Bioorganic & medicinal chemistry.

[7]  P. Wipf,et al.  2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway. , 2014, Bioorganic & medicinal chemistry letters.

[8]  N. Y. Megally Abdo,et al.  Synthesis of novel 1,2,4-triazoles, triazolothiadiazines and triazolothiadiazoles as potential anticancer agents. , 2014, European journal of medicinal chemistry.

[9]  Q. Shen,et al.  Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention , 2014, Cancers.

[10]  A. Bishayee,et al.  Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. , 2014, Biochimica et biophysica acta.

[11]  Huayun,et al.  High-Content pSTAT3/1 Imaging Assays to Screen for Selective Inhibitors of STAT3 Pathway Activation in Head and Neck Cancer Cell Lines , 2014 .

[12]  David E. Gloriam,et al.  The contribution of atom accessibility to site of metabolism models for cytochromes P450. , 2013, Molecular pharmaceutics.

[13]  D. Goldstein,et al.  STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). , 2012, International journal of oncology.

[14]  N. Neamati,et al.  Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. , 2012, Journal of medicinal chemistry.

[15]  Hualiang Jiang,et al.  Synthesis, Structure–Activity Relationship, and Pharmacophore Modeling Studies of Pyrazole‐3‐Carbohydrazone Derivatives as Dipeptidyl Peptidase IV Inhibitors , 2012, Chemical biology & drug design.

[16]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[17]  J. Grandis,et al.  STAT3 signaling: anticancer strategies and challenges. , 2011, Molecular interventions.

[18]  A. Levitzki,et al.  Signal transduction therapy of cancer. , 2010, Molecular aspects of medicine.

[19]  David E. Gloriam,et al.  SMARTCyp: A 2D Method for Prediction of Cytochrome P450-Mediated Drug Metabolism. , 2010, ACS medicinal chemistry letters.

[20]  D. Frank.  STAT3 as a central mediator of neoplastic cellular transformation. , 2007, Cancer letters.

[21]  W. Gerald,et al.  Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. , 2006, Cancer research.

[22]  J. Grandis,et al.  STAT3 as a therapeutic target in head and neck cancer , 2006, Expert opinion on biological therapy.

[23]  A. K. Roy,et al.  Facile Baylis—Hillman Reaction of Substituted 3-Isoxazolecarbaldehydes: The Impact of a Proximal Heteroatom within a Heterocycle on the Acceleration of the Reaction. , 2004 .

[24]  S. D. Patil,et al.  Synthesis and Antimicrobial Activity of Some Bridgehead Nitrogen Heterocycles. , 2001 .

[25]  N. Heindel,et al.  Improved syntheses of 5‐substituted‐4‐amino‐3‐mercapto‐(4H)‐1,2,4‐triazoles , 1976 .

[26]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[27]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.